However, the reason why Q2 and Q3 levels of VGLL4 expression is significantly associated with survival in paediatric AML patients may lie in the biological function of VGLL4. VGLL4 was found to be a novel regulator of survival in human embryonic stem cells [23] and acts as a tumour suppressor gene through its interaction with transcriptional enhanced associated domains (TEAD) (reviewed in [24]). Here, VGLL4 is linked to acute myeloid leukemia.